← Back to Clinical Trials
RecruitingNCT04130958

Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionMajor Depressive Episode
SponsorMassachusetts General Hospital
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment80
SexALL
Min Age18 Years
Max Age65 Years
Start Date2023-11-01
Completion2026-04-30
Interventions
Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with major depressive episode (MDE) or borderline personality disorder (BPD).

Eligibility Criteria

Inclusion Criteria: * 18-65 years of age * Diagnosed with BPD or MDE * Chief complaint of suicidal thoughts and behaviors Exclusion Criteria: * Neurological conditions with known structural brain lesion * Prior neurosurgical procedure * Metal in the body that is ferromagnetic or metal injury to the eyes * Epilepsy * Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt * Psychopathology not appropriate for the treatment (e.g., manic episode or psychosis) * Current alcohol dependence or active symptoms of non-alcohol psychoactive substance use withdrawal, as indicated by self-report * Inability to meet the safety criteria for MRI scanning according to the protocols of the MGH Department of Radiology * Current pregnancy

Related Trials